What does Absci Corporation do?
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody,…
What is Absci Corporation's P/E and P/B ratio?
Absci Corporation has a P/E ratio of -11.9 and a P/B ratio of 6.53.
What is Absci Corporation's debt-to-equity ratio?
Absci Corporation has a debt-to-equity ratio of 0.02.
How much does Absci Corporation owe compared with what it owns?
Absci Corporation owes $0.08 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Absci Corporation's Positivity rank?
Absci Corporation is ranked #5,466 of 6,774 companies globally and #2,977 of 4,000 in United States on PositoAI, with a Positivity Score of 17,293.
Does Absci Corporation have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Absci Corporation.
Where can I read the latest news about Absci Corporation?
Recent headlines about Absci Corporation from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Absci Corporation have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Absci Corporation's current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.